$121.1 B

LLY Mkt cap, 12-Dec-2018
Eli Lilly Cash, 30-Sep-20189 B

Eli Lilly Revenue

Eli Lilly revenue was $21.22 b in FY, 2016 which is a 6.3% year over year increase from the previous period.

Embed Graph

Eli Lilly Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

23.1b19.6b20.0b21.2b

Revenue growth, %

(15%)2%6%

Cost of goods sold

4.9b4.9b5.0b5.7b

Gross profit

18.2b14.7b14.9b15.6b

Gross profit Margin, %

79%75%75%73%

Pre tax profit

5.9b3.0b2.8b3.4b

Income tax expense

1.2b609.8m381.6m636.4m

Net Income

4.7b2.4b2.4b2.7b

Quarterly

USDQ3, 2016Q2, 2017Q3, 2017Q1, 2018

Revenue

5.7b5.7b

Pre tax profit

1.4b

Income tax expense

36.0m

Net Income

778.0m1.0b

Eli Lilly Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

3.8b3.9b3.7b4.6b

Accounts Receivable

588.4m566.7m558.6m736.9m

Inventories

2.9b2.7b3.4b3.6b

Current Assets

13.1b12.2b12.6b15.1b

PP&E

8.0b8.0b8.1b8.3b

Goodwill

1.8b4.0b4.0b

Total Assets

35.2b37.2b35.6b38.8b45.0b

Accounts Payable

1.1b1.1b1.3b1.3b

Dividends Payable

523.5m530.3m539.0m548.1m

Short-term debt

Current Liabilities

8.9b11.2b8.2b11.0b

Long-term debt

4.2b5.4b8.0b8.4b

Total Debt

4.2b5.4b8.0b8.4b

Common Stock

698.5m694.6m691.3m

Additional Paid-in Capital

5.1b5.3b5.6b5.6b

Retained Earnings

17.0b16.5b16.0b16.0b

Total Equity

17.6b15.4b14.6b14.1b

Debt to Equity Ratio

0.2 x0.3 x0.5 x0.6 x

Debt to Assets Ratio

0.1 x0.1 x0.2 x0.2 x

Financial Leverage

2 x2.4 x2.4 x2.8 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q3, 2018

Cash

3.9b3.2b3.5b9.0b

Inventories

3.0b4.3b4.1b

Current Assets

12.3b12.6b

Goodwill

4.2b

Accounts Payable

1.2b

Current Liabilities

8.2b8.4b10.4b11.5b

Long-term debt

5.3b

Total Debt

5.3b

Common Stock

699.0m693.0m690.0m

Additional Paid-in Capital

5.2b5.5b5.8b

Retained Earnings

16.2b

Eli Lilly Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.7b2.4b2.4b2.7b

Cash From Operating Activities

5.7b4.4b2.8b4.9b

Purchases of PP&E

(1.0b)(1.2b)(1.1b)(1.0b)

Cash From Investing Activities

(2.1b)(3.9b)26.8m(3.1b)

Short-term Borrowings

2.7b(2.7b)1.3b

Long-term Borrowings

(10.5m)(1.0b)(2.0b)(200.0k)

Dividends Paid

(2.1b)(2.1b)(2.1b)(2.2b)

Cash From Financing Activities

(3.8b)(75.1m)(2.9b)(559.8m)

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q2, 2016Q3, 2016Q2, 2017Q2, 2018Q3, 2018

Net Income

727.9m1.5b2.0b1.9b2.1b

Depreciation and Amortization

348.8m697.2m726.0m1.2b848.0m

Cash From Operating Activities

272.3m1.3b2.0b2.0b

Cash From Investing Activities

388.4m(80.5m)(2.0b)2.6b

Short-term Borrowings

2.3m

Long-term Borrowings

(1.0b)(1.0b)

Dividends Paid

(524.1m)(1.1b)(1.6b)(1.6b)

Cash From Financing Activities

(595.1m)(1.3b)(237.0m)
Report incorrect company information

Eli Lilly Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Phase III Trials Products

8 7 17 19

Projects in R&D Pipeline

57 57 65 66
Report incorrect company information

Eli Lilly Employee Rating

3.81630 votes
Culture & Values
3.9
Work/Life Balance
3.9
Senior Management
3.3
Salary & Benefits
3.8
Career Opportunities
3.3
Source